Nuvectis Pharma (NVCT)
(Real Time Quote from BATS)
$6.45 USD
+0.15 (2.38%)
Updated Aug 13, 2024 03:06 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Income Statements
Fiscal Year end for Nuvectis Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 23 | 19 | 13 | 0 | 0 |
Income After Depreciation & Amortization | -23 | -19 | -13 | 0 | 0 |
Non-Operating Income | 1 | 0 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -22 | -19 | -13 | 0 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -22 | -19 | -13 | 0 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -22 | -19 | -13 | 0 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | -19 | -13 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -23 | -19 | -13 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 15.56 | 12.66 | 4.27 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.43 | -1.51 | -3.02 | NA | NA |
Diluted Net EPS (GAAP) | -1.43 | -1.51 | -3.02 | NA | NA |
Fiscal Year end for Nuvectis Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 4.64 | 4.40 | 6.87 | 6.16 | 5.77 |
Income After SG&A, R&D, and Dept/Amort Expenses | -4.64 | -4.40 | -6.87 | -6.16 | -5.77 |
Non-Operating Income | 0.22 | 0.23 | 0.24 | 0.28 | 0.06 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -4.43 | -4.17 | -6.62 | -5.88 | -5.71 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.43 | -4.17 | -6.62 | -5.88 | -5.71 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.43 | -4.17 | -6.62 | -5.88 | -5.71 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 16.90 | 16.56 | 16.09 | 16.10 | 15.18 |
Diluted EPS Before Non-Recurring Items | -0.26 | -0.25 | -0.41 | -0.37 | -0.38 |
Diluted Net EPS (GAAP) | -0.26 | -0.25 | -0.41 | -0.37 | -0.38 |